85 related articles for article (PubMed ID: 11045322)
1. Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.
Bouts AH; Groothoff JW; van Amstel SP; Zweers MM; Davin JC; Krediet RT
Adv Perit Dial; 2000; 16():328-31. PubMed ID: 11045322
[TBL] [Abstract][Full Text] [Related]
2. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
3. Dialysate CA125 in stable CAPD patients: no relation with transport parameters.
Pannekeet MM; Koomen GC; Struijk DG; Krediet RT
Clin Nephrol; 1995 Oct; 44(4):248-54. PubMed ID: 8575125
[TBL] [Abstract][Full Text] [Related]
4. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
5. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
[TBL] [Abstract][Full Text] [Related]
6. Dialysate CA125 levels in children on continuous peritoneal dialysis.
Turhan P; Sever L; Caliskan S; Kasapcopur O; Sever A; Hacibekiroglu M; Arisoy N
Pediatr Nephrol; 2005 Nov; 20(11):1615-21. PubMed ID: 16133054
[TBL] [Abstract][Full Text] [Related]
7. The effect of dwell time on dialysate cancer antigen 125 appearance rates in patients on continuous ambulatory peritoneal dialysis.
Akman S; van Westrhenen R; De Waart DR; Hiralall JK; Zweers MM; Krediet RT
Adv Perit Dial; 2003; 19():24-7. PubMed ID: 14763029
[TBL] [Abstract][Full Text] [Related]
8. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
9. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of cancer antigen 125 and interleukin-15 in relation to the nutrition status of peritoneal dialysis patients.
Grzegorzewska AE; Mlot M; Leande M
Adv Perit Dial; 2004; 20():185-9. PubMed ID: 15384823
[TBL] [Abstract][Full Text] [Related]
11. Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.
Candan C; Turhan P; Sever L; Civilibal M; Canpolat N; Caliskan S; Kasapcopur O; Arisoy N
Pediatr Nephrol; 2011 May; 26(5):783-8. PubMed ID: 21279389
[TBL] [Abstract][Full Text] [Related]
12. Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome.
Jiménez C; Díaz C; Selgas R; Auxiliadora Bajo M; del Peso G; Sánchez-Tomero JA; Gonzalez-Gancedo P
Adv Perit Dial; 1999; 15():36-9. PubMed ID: 10682069
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.
Passadakis P; Panagoutsos S; Thodis E; Tsivara I; Sopassi F; Kartali S; Vargemezis V
Adv Perit Dial; 1999; 15():40-4. PubMed ID: 10682070
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in peritoneal dialysis: a longitudinal follow-up.
Zweers MM; Struijk DG; Smit W; Krediet RT
J Lab Clin Med; 2001 Feb; 137(2):125-32. PubMed ID: 11174469
[TBL] [Abstract][Full Text] [Related]
15. Differences in peritoneal equilibration test results in patients aged above or below 60 years.
Grzegorzewska AE; Leander M; Mariak I
Adv Perit Dial; 2002; 18():33-9. PubMed ID: 12402583
[TBL] [Abstract][Full Text] [Related]
16. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal cefazolin and ceftazidime effects on human peritoneal mesothelial cell release of cancer antigen-125.
Manley HJ; Elwell RJ; Bailie GR; Welch CL
Ann Pharmacother; 2004 Dec; 38(12):2035-40. PubMed ID: 15536141
[TBL] [Abstract][Full Text] [Related]
19. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():149-53. PubMed ID: 12402608
[TBL] [Abstract][Full Text] [Related]
20. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis.
Krediet RT
Perit Dial Int; 2001; 21(6):560-7. PubMed ID: 11783764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
